{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:51:52Z","timestamp":1772725912425,"version":"3.50.1"},"reference-count":38,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"BeOne Medicines Ltd"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,1,26]]},"DOI":"10.1080\/14796694.2026.2615736","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T14:09:19Z","timestamp":1769868559000},"page":"339-348","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed\/refractory chronic lymphocytic leukemia"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"first","affiliation":[{"name":"University of Washington","place":["Seattle, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4702-6772","authenticated-orcid":false,"given":"Asher","family":"Chanan-Khan","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Jacksonville, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8510-8357","authenticated-orcid":false,"given":"David","family":"Campbell","sequence":"additional","affiliation":[{"name":"Curta Inc","place":["Seattle, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8087-1143","authenticated-orcid":false,"given":"Mei","family":"Xue","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["San Carlos, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6817-7156","authenticated-orcid":false,"given":"Marjan","family":"Massoudi","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["San Carlos, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhys","family":"Williams","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["San Carlos, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["San Carlos, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"Alfred Hospital and Monash University","place":["Melbourne, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.1946"},{"key":"e_1_3_7_4_1","unstructured":"Imbruvica\u00ae (ibrutinib). Prescribing information. 2024 Dec. Available from: https:\/\/www.rxabbvie.com\/pdf\/imbruvica_pi.pdf"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007938"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05486-x"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000801"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00320-9"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024667"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251340554"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.016"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18075"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26367"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014523"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198806303182605"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6977.452"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.24330"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2006.05.002"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022839"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1324160"},{"key":"e_1_3_7_25_1","unstructured":"Symphony health integrated Dataverse (IDV) database. ICON plc.; 2025."},{"key":"e_1_3_7_26_1","unstructured":"Merative RED BOOK Online. IBM Watson. [cited 2025 Apr]. Available from: https:\/\/www.merative.com\/documents\/micromedex-red-book"},{"key":"e_1_3_7_27_1","unstructured":"Brukinsa\u00ae (zanubrutinib). Prescribing information. BeOne Medicines USA Inc; 2025 Jun. Available from: https:\/\/d1e94vsyskgtht.cloudfront.net\/brukinsa\/pdfs\/brukinsa-prescribing-information.pdf"},{"key":"e_1_3_7_28_1","unstructured":"Calquence\u00ae (acalabrutinib). Prescribing information. 2024 Jun. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/216387Orig2s000Correctedlbl.pdf"},{"key":"e_1_3_7_29_1","unstructured":"Institute for Clinical and Economic Review. Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects. Revised evidence report. 2022 Mar 17. Available from: https:\/\/icer.org\/wp-content\/uploads\/2021\/08\/ICER_Neutropenia_Evidence-Report_031722.pdf"},{"key":"e_1_3_7_30_1","unstructured":"Agency for Healthcare Research and Quality. Healthcare cost and utilization project (HCUP). 2025. Available from: https:\/\/datatools.ahrq.gov\/hcupnet\/"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00140"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01350-w"},{"key":"e_1_3_7_34_1","unstructured":"U.S Bureau of Labor Statistics. Medical care in U.S. city average all urban consumers not seasonally adjusted. 2025. Available from: https:\/\/data.bls.gov\/cgi-bin\/surveymostCPI2025"},{"key":"e_1_3_7_35_1","unstructured":"ICER\u2019s reference case for economic evaluations: elements and rationale. Institute for clinical and economic review. 2025. Available from: https:\/\/icer.org\/wp-content\/uploads\/2024\/02\/ICER_Reference-Case_For-Publication_102325.pdf"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0019"},{"key":"e_1_3_7_37_1","unstructured":"BeiGene Data on File. Real world CLL treatment use. 2024 Apr."},{"key":"e_1_3_7_38_1","unstructured":"Rituxan\u00ae (rituximab). Prescribing information. Genentech Inc. 2024 Apr. Available from: https:\/\/www.gene.com\/download\/pdf\/rituxan_prescribing.pdf"},{"key":"e_1_3_7_39_1","unstructured":"Venclexta (ventoclax). Prescribing information. AbbVie Inc.; 2024 Jul. Available from: https:\/\/www.rxabbvie.com\/pdf\/venclexta.pdf"},{"key":"e_1_3_7_40_1","unstructured":"Jaypirca\u00ae (pirtobrutinib). Prescribing information. Eli Lilly and Company; 2024 Jun. Available from: https:\/\/uspl.lilly.com\/jaypirca\/jaypirca.html#pi"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2615736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:51:50Z","timestamp":1772722310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2026.2615736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,1,26]]}},"alternative-id":["10.1080\/14796694.2026.2615736"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2026.2615736","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}